Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial.

ABSTRACT:

Purpose

Cytomegalovirus (CMV) antigens occur in glioblastoma but not in normal brains, making them desirable immunologic targets.

Patients and methods

Highly functional autologous polyclonal CMV pp65-specific T cells from patients with glioblastoma were numerically expanded under good manufacturing practice compliant conditions and administered after 3 weeks of lymphodepleting dose-dense temozolomide (100 mg/m²) treatment. The phase I component used a 3+3 design, ascending through four dose levels (5 × 10⁶-1 × 10⁸ cells). Treatment occurred every 6 weeks for four cycles. In vivo persistence and effector function of CMV-specific T cells was determined by dextramer staining and multiparameter flow cytometry in serially sampled peripheral

SUBMITTER: Weathers SP 

PROVIDER: S-EPMC9347965 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature